Norris Perne & French LLP MI trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 38.3% during the second quarter, Holdings Channel reports. The institutional investor owned 84,277 shares of the company’s stock after selling 52,381 shares during the period. Johnson & Johnson makes up about 1.4% of Norris Perne & French LLP MI’s holdings, making the stock its 29th largest position. Norris Perne & French LLP MI’s holdings in Johnson & Johnson were worth $14,960,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. RE Dickinson Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the last quarter. Morton Brown Family Wealth LLC grew its stake in shares of Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the last quarter. Advanced Research Investment Solutions LLC grew its stake in shares of Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $39,000. 68.59% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on JNJ shares. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Raymond James dropped their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Bank of America dropped their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $181.33.
Insider Buying and Selling at Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of JNJ opened at $177.01 on Thursday. The company’s 50 day moving average price is $168.35 and its 200 day moving average price is $171.28. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a market capitalization of $462.79 billion, a PE ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.60 earnings per share. Research analysts expect that Johnson & Johnson will post 10.04 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
Johnson & Johnson declared that its board has approved a stock buyback plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.